XML 80 R69.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Segment Reporting Information [Line Items]        
Profits $ 200 $ 2,887 $ 4,642 $ 6,015
Interest income 90 87 284 244
Interest expense (189) (170) (564) (513)
Equity income from affiliates 18 21 11 59
Depreciation and amortization     (3,509) (4,286)
Research and development (4,383) (1,664) (7,927) (5,475)
Restructuring costs (153) (161) (470) (386)
Total segment profits        
Segment Reporting Information [Line Items]        
Profits 6,411 6,551 18,164 17,827
Total segment profits | Pharmaceutical segment        
Segment Reporting Information [Line Items]        
Profits 5,929 6,162 16,722 16,698
Total segment profits | Other segments        
Segment Reporting Information [Line Items]        
Profits 482 389 1,442 1,129
Other profits        
Segment Reporting Information [Line Items]        
Profits (78) 21 107 341
Unallocated        
Segment Reporting Information [Line Items]        
Interest income 90 87 284 244
Interest expense (189) (170) (564) (513)
Equity income from affiliates 23 (27) 16 (13)
Depreciation and amortization (334) (365) (1,036) (1,228)
Research and development (1,829) (1,444) (4,955) (4,651)
Aggregate charge related to the formation of an oncology collaboration with AstraZeneca (2,350) 0 (2,350) 0
Amortization of purchase accounting adjustments (765) (772) (2,322) (2,933)
Restructuring costs (153) (161) (470) (386)
Gain on sale of certain migraine clinical development programs 0 40 0 40
Other unallocated, net $ (626) $ (873) $ (2,232) $ (2,713)